uniQure N.V.(QURE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,872 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
QURE Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for uniQure N.V. (QURE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores QURE at 13.9/100 on a 32-signal composite quality model, placing it at rank #2,872 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2026), uniQure N.V. reports quarterly revenue of $3.6M, net income of $-53.5M, free cash flow of $-38.4M. Top institutional holders of QURE by reported 13-F value include Avoro Capital Advisors, JPMORGAN CHASE, RTW INVESTMENTS, based on the most recent SEC filings. QURE trades on the Nasdaq exchange and files with the SEC under CIK 1590560. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QURE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for uniQure N.V. directly from SEC EDGAR. uniQure N.V.'s 13F Pro composite quality score has ranged between 11 and 16 since 2026, currently 13.9 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q1 2026
$3.6M
Net Income
Q1 2026
$-53.5M
Free Cash Flow
Q1 2026
$-38.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-40.6% YoYNet Income
+16.9% YoYOperating Income
-0.6% YoYEPS (Diluted)
+29.7% YoYTotal Assets
+48.2% YoYTotal Debt
+8.9% YoYOp. Cash Flow
+2.6% YoYFree Cash Flow
+4.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $16.1M -40.6% | $27.1M +71.2% | $15.8M -85.1% | $106.5M -79.7% | $524.0M +1296.8% | $37.5M |
| Net Income | $-199.0M +16.9% | $-239.6M +22.3% | $-308.5M -143.3% | $-126.8M -138.5% | $329.6M | — |
| Operating Income | $-185.3M -0.6% | $-184.3M +34.8% | $-282.9M -97.6% | $-143.2M -146.1% | $310.6M +347.7% | $-125.4M |
| EPS (Diluted) | $-3.46 +29.7% | $-4.92 +24.0% | $-6.47 -138.7% | $-2.71 -138.5% | $7.04 +350.5% | $-2.81 |
| Total Assets | $824.9M +48.2% | $556.5M -33.1% | $831.7M +18.0% | $705.0M -12.9% | $809.2M +137.7% | $340.4M |
| Total Debt | $71.9M +8.9% | $66.0M -55.3% | $147.6M +2.1% | $144.5M +6.6% | $135.6M +219.7% | $42.4M |
| Operating Cash Flow | $-178.0M +2.6% | $-182.7M -25.2% | $-145.9M -0.6% | $-145.1M -150.4% | $288.0M +313.6% | $-134.8M |
| Free Cash Flow | $-178.4M +4.1% | $-186.1M -21.6% | $-153.1M +5.9% | $-162.7M -160.2% | $270.5M +290.4% | $-142.1M |
Get alerted when QURE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for uniQure N.V. including:
Top Institutional Holders of QURE
Avoro Capital Advisors LLC
$309.9M6,727,777 shJPMORGAN CHASE & CO
$230.8M4,867,755 shRTW INVESTMENTS, LP
$181.5M3,941,572 shSTATE STREET CORP
$133.8M2,903,825 shabrdn plc
$131.2M2,848,117 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$118.7M2,577,700 shBlackRock, Inc.
$86.5M1,877,453 shORBIMED ADVISORS LLC
$83.3M1,807,486 shCaption Management, LLC
$75.0M1,627,600 shJANE STREET GROUP, LLC
$74.2M1,610,483 sh
| Fund | Value | Shares |
|---|---|---|
| Avoro Capital Advisors LLC | $309.9M | 6,727,777 |
| JPMORGAN CHASE & CO | $230.8M | 4,867,755 |
| RTW INVESTMENTS, LP | $181.5M | 3,941,572 |
| STATE STREET CORP | $133.8M | 2,903,825 |
| abrdn plc | $131.2M | 2,848,117 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $118.7M | 2,577,700 |
| BlackRock, Inc. | $86.5M | 1,877,453 |
| ORBIMED ADVISORS LLC | $83.3M | 1,807,486 |
| Caption Management, LLC | $75.0M | 1,627,600 |
| JANE STREET GROUP, LLC | $74.2M | 1,610,483 |
Companies Similar to QURE
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Taysha Gene Therapies, Inc.
Avalo Therapeutics, Inc.
Dianthus Therapeutics, Inc. /DE/
Voyager Therapeutics, Inc.
IDEAYA Biosciences, Inc.
Monte Rosa Therapeutics, Inc.
Nurix Therapeutics, Inc.
OCULAR THERAPEUTIX, INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put QURE on your watchlist
Track score changes the day uniQure N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is QURE a good stock to buy?
13F Pro's AI-powered analysis of uniQure N.V. (QURE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QURE are available on the QURE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. QURE is classified as a mid company.
Which hedge funds own QURE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QURE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of uniQure N.V.'s investment landscape.